普通人群队列中无创检测评估的肝纤维化与突发心力衰竭相关
基于英国生物银行数据前瞻性分析413860人,中位随访10.7年发生12527例心力衰竭。高风险NFS、FIB-4、APRI及联合纤维化评分均与心力衰竭住院或死亡风险升高相关,PNPLA3与TM6SF2多态性未减弱该关联。
要点
- 普通人群中无创肝纤维化标志物升高与心力衰竭住院或死亡风险增加相关。
- 高风险NFS的HR为1.59,FIB-4为1.69,APRI为1.85,联合评分为1.90。
- PNPLA3 rs738409 GG与TM6SF2 rs58542926 TT未减弱纤维化标志物与心力衰竭的正关联。
核心结论
- 在普通人群中,肝纤维化血清标志物与心力衰竭住院或死亡风险增加相关。
- 与肝纤维化相关的基因多态性未与心力衰竭风险升高呈正相关。
研究设计与样本
- 使用英国生物银行数据的前瞻性队列研究,共纳入413860人。
- 中位随访10.7年,发生12527例突发心力衰竭。
- 采用Cox回归估计心力衰竭发生的风险比(HR)。
- 通过基因型分层及似然比检验评估PNPLA3 rs738409和TM6SF2 rs58542926与肝纤维化的交互作用。
主要发现
- 肝纤维化与心力衰竭住院或死亡风险增加相关:多变量校正后高风险NFS的HR为1.59(95%CI 1.47-1.76,P<.0001)。
- FIB-4的HR为1.69(95%CI 1.55-1.84,P<.0001),APRI的HR为1.85(95%CI 1.56-2.19,P<.0001)。
- 联合纤维化评分的HR为1.90(95%CI 1.44-2.49,P<.0001)。
- 上述关联在代谢功能障碍相关脂肪性肝病(MASLD)、MASLD合并饮酒(Met-ALD)及有害饮酒人群中持续存在。
- PNPLA3 rs738409 GG和TM6SF2 rs58542926 TT未减弱纤维化标志物与心力衰竭的正关联;PNPLA3 rs738409与FIB-4、APRI评分及心力衰竭之间存在统计学显著交互作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The aim of this study was to determine whether liver fibrosis is associated with heart failure in a general population cohort, and if genetic polymorphisms (PNPLA3 rs738409; TM6SF2 rs58542926), linked to increased risk of liver fibrosis and decreased risk of coronary artery disease, modify this association. METHODS: Using UK Biobank data, we prospectively examined the relationship between noninvasive fibrosis markers (nonalcoholic fatty liver disease [NAFLD] fibrosis score [NFS], Fibrosis-4 [FIB-4] and aspartate transaminase [AST] to platelet ratio index [APRI]) and incident hospitalization/death from heart failure (n = 413,860). Cox-regression estimated hazard ratios (HRs) for incident heart failure. Effects of PNPLA3 and TM6SF2 on the association between liver fibrosis and heart failure were estimated by stratifying for genotype and testing for an interaction between genotype and liver fibrosis using a likelihood ratio test. RESULTS: A total of 12,527 incident cases of heart failure occurred over a median of 10.7 years. Liver fibrosis was associated with an increased risk of hospitalization or death from heart failure (multivariable adjusted high-risk NFS score HR, 1.59; 95% confidence interval [CI],1.47-1.76; P < .0001; FIB-4 HR, 1.69; 95% CI, 1.55-1.84; P < .0001; APRI HR, 1.85; 95% CI, 1.56-2.19; P < .0001; combined fibrosis scores HR, 1.90; 95% CI, 1.44-2.49; P < .0001). These associations persisted for people with metabolic dysfunction-associated steatotic liver disease (MASLD), MASLD with alcohol consumption (Met-ALD), and harmful alcohol consumption. PNPLA3 rs738409 GG and TM6SF2 rs58542926 TT did not attenuate the positive association between fibrosis markers and heart failure. For PNPLA3, a statistically significant interaction was found between PNPLA3 rs738409, FIB-4, APRI score, and heart failure. CONCLUSION: In the general population, serum markers of liver fibrosis are associated with increased hospitalization/death from heart failure. Genetic polymorphisms associated with liver fibrosis were not positively associated with elevated heart failure risk.
引用
- Hydes TJ, Kennedy OJ, Glyn-Owen K, et al. Liver Fibrosis Assessed Via Noninvasive Tests Is Associated With Incident Heart Failure in a General Population Cohort. Clin Gastroenterol Hepatol. 2024. PMID: 38723982. doi:10.1016/j.cgh.2024.03.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。